Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adicet Bio, Inc.ACET · Entity 6860 | Director · President & CEO | June 19, 2026 | June 23, 2026 |
| BRAINSTORM CELL THERAPEUTICS INC.BCLI · Entity 7869 | Director | October 24, 2018 | December 21, 2018 |
| Karyopharm Therapeutics Inc.KPTI · Entity 781 | Director | May 21, 2026 | May 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adicet Bio, Inc.
Report date June 19, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.10 · Expires 2036-06-18 | Direct | 55,000 |
Reported balance
After 2026-06-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-19 · Grant · Acquired 55,000 · Balance 55,000 F1: 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the grant date with partial acceleration tied to certain performance milestones, provided that the Reporting Person maintains a service relationship with the Issuer as of the applicable vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the grant date with partial acceleration tied to certain performance milestones, provided that the Reporting Person maintains a service relationship with the Issuer as of the applicable vesting dates.
BRAINSTORM CELL THERAPEUTICS INC.
Report date October 24, 2018 · Filed December 21, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,000 |
Reported balance
After 2018-10-24 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-10-24 · Gift · Disposed 121,558 · Balance 4,000 F1: These shares were previously reported as directly beneficially owned but on October 24, 2018 were gifted to an irrevocable trust for the benefit of the reporting person and other individuals. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. F2: Includes the November 30, 2018 acquisition of 2,000 shares by the reporting person, as reported on Form 4 filed November 30, 2018. |
| Common StockSEC Table I · non-derivative | IndirectBy The C. Schor Irrevocable Trust | 121,558 |
Reported balance
After 2018-10-24 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2018-10-24 · Gift · Acquired 121,558 · Balance 121,558 F1: These shares were previously reported as directly beneficially owned but on October 24, 2018 were gifted to an irrevocable trust for the benefit of the reporting person and other individuals. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were previously reported as directly beneficially owned but on October 24, 2018 were gifted to an irrevocable trust for the benefit of the reporting person and other individuals. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
F2: Includes the November 30, 2018 acquisition of 2,000 shares by the reporting person, as reported on Form 4 filed November 30, 2018.
Karyopharm Therapeutics Inc.
Report date May 21, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,508 |
Reported balance
After 2026-05-21 transaction · row 1
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 15,508 · Balance 15,508 F1: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest 100% on May 21, 2027; however, delivery of the shares is deferred until the earlier of (a) the date of the director's separation from service to Karyopharm Therapeutics Inc. and (b) a change-in-control event. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest 100% on May 21, 2027; however, delivery of the shares is deferred until the earlier of (a) the date of the director's separation from service to Karyopharm Therapeutics Inc. and (b) a change-in-control event.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 12, 2022 Filed Sep 13, 2022 20:59 UTC | Adicet Bio, Inc. ACET · Entity 6860 | SaleCommon Stock | 200 | $18.00 | $3,600.00 |
DisclosureSEC source: 0001209191-22-049721 · doc4.xml · nonDerivative · entry 3 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 143,060 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · ownership.nature: Represents shares held directly by The C. Schor IRRV Trust, an irrevocable family trust having an independent trustee. Read SEC document |
| September 12, 2022 Filed Sep 13, 2022 20:59 UTC | Adicet Bio, Inc. ACET · Entity 6860 | SaleCommon Stock | 66,747 | $16.77 | $1,119,307.14 |
DisclosureSEC source: 0001209191-22-049721 · doc4.xml · nonDerivative · entry 2 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $16.50 to $16.96, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: Represents shares held directly by The I. Schor IRRV Trust, an irrevocable family trust having an independent trustee. Read SEC document |
| September 09, 2022 Filed Sep 13, 2022 20:59 UTC | Adicet Bio, Inc. ACET · Entity 6860 | SaleCommon Stock | 8,094 | $16.51 | $133,601.18 |
DisclosureSEC source: 0001209191-22-049721 · doc4.xml · nonDerivative · entry 1 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 66,747 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $16.50 to $16.56, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the Securities and Exchange Commission ("SEC") staff upon request. F3 · ownership.nature: Represents shares held directly by The I. Schor IRRV Trust, an irrevocable family trust having an independent trustee. Read SEC document |
| August 04, 2022 Filed Aug 9, 2022 00:32 UTC | Adicet Bio, Inc. ACET · Entity 6860 | Tax withholdingCommon Stock | 21,288 | $18.25 | $388,506.00 |
DisclosureSEC source: 0001209191-22-044905 · doc4.xml · nonDerivative · entry 4 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,712 Read SEC document |
| August 04, 2022 Filed Aug 9, 2022 00:32 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantCommon Stock | 48,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-044905 · doc4.xml · nonDerivative · entry 3 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,000 F3 · balance_after: The Reporting Person was issued 240,000 Restricted Stock Units ("RSUs") on October 1, 2021, as previously reported on a Form 4 filed by the Reporting Person on October 5, 2021. Each RSU represents a contingent right to receive one share of common stock. A total of 96,000 of the RSUs shall vest in two (2) annual installments of 20% of the shares vesting, with the first tranche vesting on October 1, 2022 and the second tranche vesting on October 1, 2023. A total of 144,000 of the RSUs shall vest upon achievements of specific milestones outlined in the Reporting Person's Restricted Stock Unit Agreement. On August 4, 2022, upon the occurrence of the third performance milestone, 48,000 of the RSUs vested. The RSUs may be settled only by delivering shares of common stock, and thus, the grant is being reported in Table I as allowed per SEC guidance. Read SEC document |
| July 06, 2022 Filed Aug 9, 2022 00:32 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GiftCommon Stock | 53,424 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-044905 · doc4.xml · nonDerivative · entry 2 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 143,260 F1 · kind: Represents the transfer of shares held by the Reporting Person to The C. Schor IRRV Trust for no consideration. F2 · ownership.nature: Represents shares held directly by The C. Schor IRRV Trust, an irrevocable family trust having an independent trustee. Read SEC document |
| July 06, 2022 Filed Aug 9, 2022 00:32 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GiftCommon Stock | 53,424 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-044905 · doc4.xml · nonDerivative · entry 1 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,000 F1 · kind: Represents the transfer of shares held by the Reporting Person to The C. Schor IRRV Trust for no consideration. Read SEC document |
| May 19, 2022 Filed May 20, 2022 20:12 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantNonstatutory Stock Option (right to buy) · Derivative | 23,900 | $0.00 Strike: $5.65 | $0.00 |
DisclosureSEC source: 0001209191-22-030986 · doc4.xml · derivative · entry 1 Schor Chen · CIK 0001340875 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,900 Underlying: Common Stock · 23,900 shares Expires 2032-05-18 F1 · derivative.exercise_date: This option vests as to 100% of the underlying shares on the earlier of May 19, 2023 or the next annual meeting of stockholders of Karyopharm Therapeutics Inc. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 02:31 UTC | Adicet Bio, Inc. ACET · Entity 6860 | Tax withholdingCommon Stock | 21,288 | $14.27 | $303,779.76 |
DisclosureSEC source: 0001209191-22-010475 · doc4.xml · nonDerivative · entry 2 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,424 Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 02:31 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantCommon Stock | 48,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-010475 · doc4.xml · nonDerivative · entry 1 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,712 F1 · balance_after: The Reporting Person was issued 240,000 Restricted Stock Units ("RSUs") on October 1, 2021, as previously reported on a Form 4 filed by the Reporting Person on October 5, 2021. Each RSU represents a contingent right to receive one share of common stock. A total of 96,000 of the RSUs shall vest in two (2) annual installments of 20% of the shares vesting, with the first tranche vesting on October 1, 2022 and the second tranche vesting on October 1, 2023. A total of 144,000 of the RSUs shall vest upon achievements of specific milestones outlined in the Reporting Persons Restricted Stock Unit Agreement. On February 14, 2022, upon the occurrence of the second performance milestone, 48,000 of the RSUs vested. The RSUs may be settled only by delivering shares of common stock, and thus, the grant is being reported in Table I as allowed per SEC guidance. Read SEC document |
| January 28, 2022 Filed Feb 2, 2022 01:40 UTC | Adicet Bio, Inc. ACET · Entity 6860 | Tax withholdingCommon Stock | 21,288 | $11.69 | $248,856.72 |
DisclosureSEC source: 0001209191-22-006132 · doc4.xml · nonDerivative · entry 2 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,712 Read SEC document |
| January 28, 2022 Filed Feb 2, 2022 01:40 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantCommon Stock | 48,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006132 · doc4.xml · nonDerivative · entry 1 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,000 F1 · balance_after: The Reporting Person was issued 240,000 Restricted Stock Units ("RSUs") on October 1, 2021, as previously reported on a Form 4 filed by the Reporting Person on October 5, 2021. Each RSU represents a contingent right to receive one share of common stock. A total of 96,000 of the RSUs shall vest in two (2) annual installments of 20% of the shares vesting, with the first tranche vesting on October 1, 2022 and the second tranche vesting on October 1, 2023. A total of 144,000 of the RSUs shall vest upon achievements of specific milestones outlined in the Reporting Persons Restricted Stock Unit Agreement. On January 28, 2022, upon the occurrence of the first performance milestone, 48,000 of the RSUs vested. The RSUs may be settled only by delivering shares of common stock, and thus, the grant is being reported in Table I as allowed per SEC guidance. Read SEC document |
| January 07, 2022 Filed Jan 11, 2022 21:28 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 295,000 | $0.00 Strike: $15.52 | $0.00 |
DisclosureSEC source: 0001209191-22-002860 · doc4.xml · derivative · entry 1 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,000 Underlying: Common Stock · 295,000 shares Expires 2032-01-06 F1 · derivative.exercise_date: 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the Grant Date, provided that the Reporting Person maintains a service relationship with the Company as of the applicable vesting dates. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 21:14 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantCommon Stock | 240,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-059577 · doc4.xml · nonDerivative · entry 1 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,000 F1 · shares: The Reporting Person was issued Restricted Stock Units ("RSU"). Each RSU represents a contingent right to receive one share of common stock. The RSUs shall vest in two (2) annual installments of 20% of the shares vesting, with the first tranche vesting on October 1, 2022 and the second tranche vesting on October 1, 2023. The remaining shares shall vest upon achievements of specific milestones outlined in the Reporting Persons Restricted Stock Unit Agreement. The RSUs may be settled only by delivering shares of common stock, and thus, the grant is being reported in Table I as allowed per SEC guidance. Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 20:25 UTC | Adicet Bio, Inc. ACET · Entity 6860 | SaleCommon Stock | 8,982 | $10.53 | $94,611.00 |
DisclosureSEC source: 0001209191-21-042000 · doc4.xml · nonDerivative · entry 2 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 89,836 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $10.32 to $10.86, inclusive. F4 · ownership.nature: Represents shares held directly by an irrevocable family trust having an independent trustee. Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 20:25 UTC | Adicet Bio, Inc. ACET · Entity 6860 | SaleCommon Stock | 7,484 | $10.53 | $78,831.97 |
DisclosureSEC source: 0001209191-21-042000 · doc4.xml · nonDerivative · entry 1 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 74,841 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $10.32 to $10.86, inclusive. F3 · ownership.nature: Represents shares held directly by an irrevocable family trust having an independent trustee. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 23:12 UTC | Adicet Bio, Inc. ACET · Entity 6860 | SaleCommon Stock | 8,982 | $12.06 | $108,278.91 |
DisclosureSEC source: 0001209191-21-038758 · doc4.xml · nonDerivative · entry 2 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 98,818 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $11.60 to $12.39, inclusive. F4 · ownership.nature: Represents shares held directly by an irrevocable family trust having an independent trustee. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 23:12 UTC | Adicet Bio, Inc. ACET · Entity 6860 | SaleCommon Stock | 7,484 | $12.06 | $90,220.37 |
DisclosureSEC source: 0001209191-21-038758 · doc4.xml · nonDerivative · entry 1 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 82,325 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $11.60 to $12.39, inclusive. F3 · ownership.nature: Represents shares held directly by an irrevocable family trust having an independent trustee. Read SEC document |
| May 21, 2021 Filed May 21, 2021 21:36 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantNonstatutory Stock Option (right to buy) · Derivative | 23,900 | $0.00 Strike: $9.42 | $0.00 |
DisclosureSEC source: 0001209191-21-035031 · doc4.xml · derivative · entry 1 Schor Chen · CIK 0001340875 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,900 Underlying: Common Stock · 23,900 shares Expires 2031-05-20 F1 · derivative.exercise_date: This option vests as to 100% of the underlying shares on the earlier of May 21, 2022 or the next annual meeting of stockholders of Karyopharm Therapeutics Inc. (the "Issuer"), provided that the reporting person continues to serve as a director of the Issuer through such date. Read SEC document |
| May 19, 2021 Filed May 21, 2021 20:34 UTC | Adicet Bio, Inc. ACET · Entity 6860 | SaleCommon Stock | 733 | $13.73 | $10,062.40 |
DisclosureSEC source: 0001209191-21-034929 · doc4.xml · nonDerivative · entry 4 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 107,800 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $13.69 to $13.79, inclusive. F5 · ownership.nature: Represents shares held directly by an irrevocable family trust having an independent trustee. Read SEC document |
| May 19, 2021 Filed May 21, 2021 20:34 UTC | Adicet Bio, Inc. ACET · Entity 6860 | SaleCommon Stock | 8,249 | $13.42 | $110,727.98 |
DisclosureSEC source: 0001209191-21-034929 · doc4.xml · nonDerivative · entry 3 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 108,533 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $12.69 to $13.66, inclusive. F5 · ownership.nature: Represents shares held directly by an irrevocable family trust having an independent trustee. Read SEC document |
| May 19, 2021 Filed May 21, 2021 20:34 UTC | Adicet Bio, Inc. ACET · Entity 6860 | SaleCommon Stock | 612 | $13.73 | $8,401.35 |
DisclosureSEC source: 0001209191-21-034929 · doc4.xml · nonDerivative · entry 2 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 89,809 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $13.69 to $13.79, inclusive. F3 · ownership.nature: Represents shares held directly by an irrevocable family trust having an independent trustee. Read SEC document |
| May 19, 2021 Filed May 21, 2021 20:34 UTC | Adicet Bio, Inc. ACET · Entity 6860 | SaleCommon Stock | 6,872 | $13.42 | $92,244.23 |
DisclosureSEC source: 0001209191-21-034929 · doc4.xml · nonDerivative · entry 1 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 90,421 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $12.69 to $13.66, inclusive. F3 · ownership.nature: Represents shares held directly by an irrevocable family trust having an independent trustee. Read SEC document |
| May 05, 2021 Filed May 7, 2021 20:02 UTC | Adicet Bio, Inc. ACET · Entity 6860 | SaleCommon Stock | 3,670 | $14.70 | $53,951.20 |
DisclosureSEC source: 0001209191-21-030874 · doc4.xml · nonDerivative · entry 4 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 116,782 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $14.53 to $15.04, inclusive. F5 · ownership.nature: Represents shares held directly by an irrevocable family trust having an independent trustee. Read SEC document |
| May 05, 2021 Filed May 7, 2021 20:02 UTC | Adicet Bio, Inc. ACET · Entity 6860 | SaleCommon Stock | 5,312 | $13.90 | $73,813.96 |
DisclosureSEC source: 0001209191-21-030874 · doc4.xml · nonDerivative · entry 3 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 120,452 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $13.51 to $14.48, inclusive. F5 · ownership.nature: Represents shares held directly by an irrevocable family trust having an independent trustee. Read SEC document |
| May 05, 2021 Filed May 7, 2021 20:02 UTC | Adicet Bio, Inc. ACET · Entity 6860 | SaleCommon Stock | 3,058 | $14.70 | $44,954.43 |
DisclosureSEC source: 0001209191-21-030874 · doc4.xml · nonDerivative · entry 2 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 97,293 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $14.53 to $15.04, inclusive. F3 · ownership.nature: Represents shares held directly by an irrevocable family trust having an independent trustee. Read SEC document |
| May 05, 2021 Filed May 7, 2021 20:02 UTC | Adicet Bio, Inc. ACET · Entity 6860 | SaleCommon Stock | 4,426 | $13.90 | $61,502.37 |
DisclosureSEC source: 0001209191-21-030874 · doc4.xml · nonDerivative · entry 1 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 100,351 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $13.51 to $14.48, inclusive. F3 · ownership.nature: Represents shares held directly by an irrevocable family trust having an independent trustee. Read SEC document |
| April 20, 2021 Filed Apr 22, 2021 20:34 UTC | Adicet Bio, Inc. ACET · Entity 6860 | SaleCommon Stock | 7,484 | $12.01 | $89,846.17 |
DisclosureSEC source: 0000899243-21-016753 · doc4.xml · nonDerivative · entry 2 Schor Chen · CIK 0001340875 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 104,777 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $11.76 to $12.27, inclusive. F4 · ownership.nature: Represents 104,777 shares held directly by an irrevocable family trust having an independent trustee. Read SEC document |
| April 20, 2021 Filed Apr 22, 2021 20:34 UTC | Adicet Bio, Inc. ACET · Entity 6860 | SaleCommon Stock | 8,982 | $12.01 | $107,829.81 |
DisclosureSEC source: 0000899243-21-016753 · doc4.xml · nonDerivative · entry 1 Schor Chen · CIK 0001340875 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 125,764 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $11.76 to $12.27, inclusive. F3 · ownership.nature: Represents 125,764 shares held directly by an irrevocable family trust having an independent trustee. Read SEC document |
| April 06, 2021 Filed Apr 8, 2021 20:37 UTC | Adicet Bio, Inc. ACET · Entity 6860 | SaleCommon Stock | 7,484 | $13.04 | $97,583.88 |
DisclosureSEC source: 0000899243-21-015390 · doc4.xml · nonDerivative · entry 2 Schor Chen · CIK 0001340875 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 112,261 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $12.61 to $13.38, inclusive. F4 · ownership.nature: Represents 112,261 shares held directly by an irrevocable family trust having an independent trustee. Read SEC document |
| April 06, 2021 Filed Apr 8, 2021 20:37 UTC | Adicet Bio, Inc. ACET · Entity 6860 | SaleCommon Stock | 8,982 | $13.04 | $117,116.30 |
DisclosureSEC source: 0000899243-21-015390 · doc4.xml · nonDerivative · entry 1 Schor Chen · CIK 0001340875 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 134,746 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $12.61 to $13.38, inclusive. F3 · ownership.nature: Represents 134,746 shares held directly by an irrevocable family trust having an independent trustee. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 22:48 UTC | Adicet Bio, Inc. ACET · Entity 6860 | SaleCommon Stock | 4,500 | $13.22 | $59,490.00 |
DisclosureSEC source: 0000899243-21-014405 · doc4.xml · nonDerivative · entry 4 Schor Chen · CIK 0001340875 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 119,745 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $12.93 to $13.62, inclusive. F5 · ownership.nature: Represents 119,745 shares held directly by an irrevocable family trust having an independent trustee. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 22:48 UTC | Adicet Bio, Inc. ACET · Entity 6860 | SaleCommon Stock | 5,400 | $13.22 | $71,388.00 |
DisclosureSEC source: 0000899243-21-014405 · doc4.xml · nonDerivative · entry 3 Schor Chen · CIK 0001340875 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 143,728 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $11.88 to $12.87, inclusive. F4 · ownership.nature: Represents 143,728 shares held directly by an irrevocable family trust having an independent trustee. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 22:48 UTC | Adicet Bio, Inc. ACET · Entity 6860 | SaleCommon Stock | 2,984 | $12.30 | $36,703.20 |
DisclosureSEC source: 0000899243-21-014405 · doc4.xml · nonDerivative · entry 2 Schor Chen · CIK 0001340875 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 124,245 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $12.93 to $13.62, inclusive. F5 · ownership.nature: Represents 119,745 shares held directly by an irrevocable family trust having an independent trustee. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 22:48 UTC | Adicet Bio, Inc. ACET · Entity 6860 | SaleCommon Stock | 3,582 | $12.30 | $44,058.60 |
DisclosureSEC source: 0000899243-21-014405 · doc4.xml · nonDerivative · entry 1 Schor Chen · CIK 0001340875 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 149,128 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $11.88 to $12.87, inclusive. F4 · ownership.nature: Represents 143,728 shares held directly by an irrevocable family trust having an independent trustee. Read SEC document |
| March 16, 2021 Filed Mar 19, 2021 01:55 UTC | Adicet Bio, Inc. ACET · Entity 6860 | SaleCommon Stock | 2,089 | $15.66 | $32,713.74 |
DisclosureSEC source: 0000899243-21-012698 · doc4.xml · nonDerivative · entry 4 Schor Chen · CIK 0001340875 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 127,229 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $15.50 to $16.02, inclusive. F5 · ownership.nature: Represents 127,229 shares held directly by an irrevocable family trust having an independent trustee. Read SEC document |
| March 16, 2021 Filed Mar 19, 2021 01:55 UTC | Adicet Bio, Inc. ACET · Entity 6860 | SaleCommon Stock | 2,508 | $15.07 | $37,795.56 |
DisclosureSEC source: 0000899243-21-012698 · doc4.xml · nonDerivative · entry 3 Schor Chen · CIK 0001340875 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 152,710 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $14.49 to $15.48, inclusive. F4 · ownership.nature: Represents 152,710 shares held directly by an irrevocable family trust having an independent trustee. Read SEC document |
| March 16, 2021 Filed Mar 19, 2021 01:55 UTC | Adicet Bio, Inc. ACET · Entity 6860 | SaleCommon Stock | 5,395 | $15.66 | $84,485.70 |
DisclosureSEC source: 0000899243-21-012698 · doc4.xml · nonDerivative · entry 2 Schor Chen · CIK 0001340875 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 129,318 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $15.50 to $16.02, inclusive. F5 · ownership.nature: Represents 127,229 shares held directly by an irrevocable family trust having an independent trustee. Read SEC document |
| March 16, 2021 Filed Mar 19, 2021 01:55 UTC | Adicet Bio, Inc. ACET · Entity 6860 | SaleCommon Stock | 6,474 | $15.07 | $97,563.18 |
DisclosureSEC source: 0000899243-21-012698 · doc4.xml · nonDerivative · entry 1 Schor Chen · CIK 0001340875 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 155,218 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $14.49 to $15.48, inclusive. F4 · ownership.nature: Represents 152,710 shares held directly by an irrevocable family trust having an independent trustee. Read SEC document |
| March 16, 2021 Filed Apr 1, 2021 22:43 UTC Amendment | Adicet Bio, Inc. ACET · Entity 6860 | SaleCommon Stock | 2,089 | $15.66 | $32,713.74 |
DisclosureSEC source: 0000899243-21-014399 · doc4a.xml · nonDerivative · entry 4 Schor Chen · CIK 0001340875 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 127,229 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $15.50 to $16.02, inclusive. F5 · ownership.nature: Represents 127,229 shares held directly by an irrevocable family trust having an independent trustee. Read SEC document |
| March 16, 2021 Filed Apr 1, 2021 22:43 UTC Amendment | Adicet Bio, Inc. ACET · Entity 6860 | SaleCommon Stock | 2,508 | $15.07 | $37,795.56 |
DisclosureSEC source: 0000899243-21-014399 · doc4a.xml · nonDerivative · entry 3 Schor Chen · CIK 0001340875 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 152,710 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $14.49 to $15.48, inclusive. F4 · ownership.nature: Represents 152,710 shares held directly by an irrevocable family trust having an independent trustee. Read SEC document |
| March 16, 2021 Filed Apr 1, 2021 22:43 UTC Amendment | Adicet Bio, Inc. ACET · Entity 6860 | SaleCommon Stock | 5,395 | $15.66 | $84,485.70 |
DisclosureSEC source: 0000899243-21-014399 · doc4a.xml · nonDerivative · entry 2 Schor Chen · CIK 0001340875 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 129,318 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $15.50 to $16.02, inclusive. F5 · ownership.nature: Represents 127,229 shares held directly by an irrevocable family trust having an independent trustee. Read SEC document |
| March 16, 2021 Filed Apr 1, 2021 22:43 UTC Amendment | Adicet Bio, Inc. ACET · Entity 6860 | SaleCommon Stock | 6,474 | $15.07 | $97,563.18 |
DisclosureSEC source: 0000899243-21-014399 · doc4a.xml · nonDerivative · entry 1 Schor Chen · CIK 0001340875 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 155,218 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $14.49 to $15.48, inclusive. F4 · ownership.nature: Represents 152,710 shares held directly by an irrevocable family trust having an independent trustee. Read SEC document |
| February 12, 2021 Filed Feb 18, 2021 02:08 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 421,600 | $0.00 Strike: $16.82 | $0.00 |
DisclosureSEC source: 0000899243-21-007022 · doc4.xml · derivative · entry 1 Schor Chen · CIK 0001340875 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 421,600 Underlying: Common Stock · 421,600 shares Expires 2031-02-11 F1 · derivative.exercise_date: 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the Vesting Commencement date, provided that the Reporting Person remains in continuous service as of the applicable vesting dates. Read SEC document |
| January 25, 2021 Filed Apr 1, 2021 22:43 UTC Amendment | Adicet Bio, Inc. ACET · Entity 6860 | GiftCommon Stock | 27,014 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-014399 · doc4a.xml · nonDerivative · entry 9 Schor Chen · CIK 0001340875 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F10 · shares: Represents 27,014 shares transferred by gift by a grantor retained annuity trust of which the Reporting Person is the trustee to an irrevocable family trust having an independent trustee. The transaction is reportable on Form 5, but the Reporting Person is voluntarily reporting early on Form 4. F10 · price: Represents 27,014 shares transferred by gift by a grantor retained annuity trust of which the Reporting Person is the trustee to an irrevocable family trust having an independent trustee. The transaction is reportable on Form 5, but the Reporting Person is voluntarily reporting early on Form 4. F10 · ownership.nature: Represents 27,014 shares transferred by gift by a grantor retained annuity trust of which the Reporting Person is the trustee to an irrevocable family trust having an independent trustee. The transaction is reportable on Form 5, but the Reporting Person is voluntarily reporting early on Form 4. Read SEC document |
| January 25, 2021 Filed Apr 1, 2021 22:43 UTC Amendment | Adicet Bio, Inc. ACET · Entity 6860 | GiftCommon Stock | 19,286 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-014399 · doc4a.xml · nonDerivative · entry 8 Schor Chen · CIK 0001340875 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F9 · shares: Represents 19,286 shares transferred by gift by a grantor retained annuity trust of which the Reporting Person's spouse is the trustee to an irrevocable family trust having an independent trustee. The transaction is reportable on Form 5, but the Reporting Person is voluntarily reporting early on Form 4. F9 · price: Represents 19,286 shares transferred by gift by a grantor retained annuity trust of which the Reporting Person's spouse is the trustee to an irrevocable family trust having an independent trustee. The transaction is reportable on Form 5, but the Reporting Person is voluntarily reporting early on Form 4. F9 · ownership.nature: Represents 19,286 shares transferred by gift by a grantor retained annuity trust of which the Reporting Person's spouse is the trustee to an irrevocable family trust having an independent trustee. The transaction is reportable on Form 5, but the Reporting Person is voluntarily reporting early on Form 4. Read SEC document |
| January 22, 2021 Filed Apr 1, 2021 22:43 UTC Amendment | Adicet Bio, Inc. ACET · Entity 6860 | GiftCommon Stock | 23,570 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-014399 · doc4a.xml · nonDerivative · entry 7 Schor Chen · CIK 0001340875 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F8 · shares: Represents 23,570 shares transferred by gift by a revocable family trust of which the Reporting Person is the trustee to an irrevocable family trust having an independent trustee. The transaction is reportable on Form 5, but the Reporting Person is voluntarily reporting early on Form 4. F8 · price: Represents 23,570 shares transferred by gift by a revocable family trust of which the Reporting Person is the trustee to an irrevocable family trust having an independent trustee. The transaction is reportable on Form 5, but the Reporting Person is voluntarily reporting early on Form 4. F8 · ownership.nature: Represents 23,570 shares transferred by gift by a revocable family trust of which the Reporting Person is the trustee to an irrevocable family trust having an independent trustee. The transaction is reportable on Form 5, but the Reporting Person is voluntarily reporting early on Form 4. Read SEC document |
| January 22, 2021 Filed Apr 1, 2021 22:43 UTC Amendment | Adicet Bio, Inc. ACET · Entity 6860 | GiftCommon Stock | 22,985 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-014399 · doc4a.xml · nonDerivative · entry 6 Schor Chen · CIK 0001340875 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F7 · shares: Represents 22,985 shares transferred by gift by a revocable family trust of which the Reporting Person is the trustee to an irrevocable family trust having an independent trustee. The transaction is reportable on Form 5, but the Reporting Person is voluntarily reporting early on Form 4. F7 · price: Represents 22,985 shares transferred by gift by a revocable family trust of which the Reporting Person is the trustee to an irrevocable family trust having an independent trustee. The transaction is reportable on Form 5, but the Reporting Person is voluntarily reporting early on Form 4. F7 · ownership.nature: Represents 22,985 shares transferred by gift by a revocable family trust of which the Reporting Person is the trustee to an irrevocable family trust having an independent trustee. The transaction is reportable on Form 5, but the Reporting Person is voluntarily reporting early on Form 4. Read SEC document |
| January 22, 2021 Filed Apr 1, 2021 22:43 UTC Amendment | Adicet Bio, Inc. ACET · Entity 6860 | GiftCommon Stock | 26,070 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-014399 · doc4a.xml · nonDerivative · entry 5 Schor Chen · CIK 0001340875 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F6 · shares: Represents 26,070 shares transferred by gift by the Reporting Person to an irrevocable family trust having an independent trustee. The transaction is reportable on Form 5, but the Reporting Person is voluntarily reporting early on Form 4. F6 · price: Represents 26,070 shares transferred by gift by the Reporting Person to an irrevocable family trust having an independent trustee. The transaction is reportable on Form 5, but the Reporting Person is voluntarily reporting early on Form 4. F6 · ownership.direct: Represents 26,070 shares transferred by gift by the Reporting Person to an irrevocable family trust having an independent trustee. The transaction is reportable on Form 5, but the Reporting Person is voluntarily reporting early on Form 4. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 21:30 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 240,000 | $0.00 Strike: $13.27 | $0.00 |
DisclosureSEC source: 0000899243-21-002190 · doc4.xml · derivative · entry 1 Schor Chen · CIK 0001340875 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,000 Underlying: Common Stock · 240,000 shares Expires 2031-01-12 F1 · derivative.exercise_date: 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the Vesting Commencement date, provided that the Reporting Person remains in continuous service as of the applicable vesting dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.